As of 2026-04-08, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (50.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.46 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -139.3%.
The range of the Relative Valuation is (47.92) - (50.81) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.6x - 23.2x | 21.5x |
| Forward P/E multiples | 19.9x - 21.1x | 20.8x |
| Fair Price | (47.92) - (50.81) | (50.93) |
| Upside | -137.0% - -139.2% | -139.3% |
| Date | P/E |